Northern Trust
CTXR icon

Northern Trust’s Citius Pharmaceuticals CTXR Stock Holding History

Northern Trust’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.6K Hold
43,974
– – ﹤0.01% 4276
2025
Q4 		$34.2K Buy
43,974
+16,949
+63% +$21.2K ﹤0.01% 4337
2025
Q3 		$33.5K Buy
27,025
+12,652
+88% +$17.6K ﹤0.01% 4330
2025
Q2 		$22.9K Sell
14,373
-800
-5% -$733 ﹤0.01% 4324
2025
Q1 		$22.6K Buy
15,173
+2,400
+19% +$5.74K ﹤0.01% 4330
2024
Q4 		$51.1K Sell
12,773
-1
-0% -$7 ﹤0.01% 4251
2024
Q3 		$160K Sell
12,774
-29,428
-70% -$495K ﹤0.01% 3947
2024
Q2 		$616K Sell
42,202
-2,610
-6% -$46.8K ﹤0.01% 3428
2024
Q1 		$1.01M Buy
44,812
+3,007
+7% +$54.9K ﹤0.01% 3305
2023
Q4 		$791K Sell
41,805
-366
-0.9% -$6.94K ﹤0.01% 3392
2023
Q3 		$722K Buy
42,171
+1,025
+2% +$24.4K ﹤0.01% 3397
2023
Q2 		$1.23M Buy
41,146
+31,336
+319% +$1.03M ﹤0.01% 3273
2023
Q1 		$287K Buy
9,810
+281
+3% +$8.1K ﹤0.01% 3688
2022
Q4 		$188K Hold
9,529
– – ﹤0.01% 3895
2022
Q3 		$289K Sell
9,529
-19
-0.2% -$522 ﹤0.01% 3695
2022
Q2 		$220K Sell
9,548
-32,989
-78% -$904K ﹤0.01% 3878
2022
Q1 		$1.9M Buy
42,537
+2,542
+6% +$100K ﹤0.01% 3128
2021
Q4 		$1.54M Sell
39,995
-907
-2% -$41.1K ﹤0.01% 3354
2021
Q3 		$2.08M Sell
40,902
-11,038
-21% -$554K ﹤0.01% 3272
2021
Q2 		$4.52M Buy
51,940
+43,050
+484% +$2.59M ﹤0.01% 2901
2021
Q1 		$396K Buy
8,890
+5,809
+189% +$231K ﹤0.01% 3889
2020
Q4 		$79K Buy
3,081
+1,406
+84% +$36.7K ﹤0.01% 4163
2020
Q3 		$44K Buy
1,675
+424
+34% +$12K ﹤0.01% 4120
2020
Q2 		$35K Buy
1,251
+573
+85% +$12.5K ﹤0.01% 4099
2020
Q1 		$10K Buy
+678
New +$14.3K ﹤0.01% 4148

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust's CTXR Position: Q1 2026 in Review

Northern Trust held its Citius Pharmaceuticals (CTXR) position steady in Q1 2026 at 43,974 shares worth $39.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4276.

Northern Trust first reported a position in CTXR in Q1 2020 and has held it in 25 quarters since. The position peaked at $4.52M in Q2 2021. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Northern Trust held 43,974 shares of Citius Pharmaceuticals worth $39.6K as of Q1 2026.
  • Northern Trust left its Citius Pharmaceuticals share count unchanged in Q1 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4276 holding.
  • Northern Trust first reported a position in Citius Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Northern Trust's Citius Pharmaceuticals position peaked at $4.52M in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.